Navigation Links
RI Hospital first in country to enroll patient in new study for recurrent chest wall breast cancer
Date:7/20/2009

PROVIDENCE -- Rhode Island Hospital is one of only four sites across the country to participate in a new clinical trial called the DIGNITY Study. The study will investigate the effectiveness of a chemotherapeutic agent, ThermoDox, used in conjunction with mild hyperthermia (a form of heat therapy) for treating recurrent chest wall breast cancer.

Recurrent chest wall (RCW) breast cancer is a return of breast cancer on the chest wall, most commonly presenting in the skin overlying the mastectomy scar, affecting approximately 20,000 to 30,000 women each year in the United States. Following a mastectomy, RCW disease will usually present as a small lump in the mastectomy scar or under the skin of the chest or abdominal area. It may be visible or can be felt under the skin, and often goes undetected for some time as it may be mistaken for a leftover stitch or scar tissue from the mastectomy surgery. A significant number of women who are diagnosed with RCW disease frequently cannot be treated with further surgery, radiation or chemotherapy because their available treatment options have been exhausted. As a result, these women often face a poor prognosis.

Rhode Island Hospital is the only hospital in New England to participate in the DIGNITY study that will test 100 patients nationally with an encapsulated chemotherapeutic agent called ThermoDox combined with hyperthermia treatment. ThermoDox is a heat-activated version of an approved and frequently used oncology drug for the treatment of a wide range of cancers, including breast cancer.

Rhode Island Hospital was the first to enroll and treat a patient. That patient has undergone the first three of a 6-cycle course of treatment. Brigid O'Connor, MD, PhD, a radiation oncologist at Rhode Island Hospital, is the principal investigator for the trial in Rhode Island.

According to O'Connor, "We treated our first patient recently and she tolerated the procedure well. I am excited to see her response to this new treatment." She continues, "The rapid development of ThermoDox is warranted so we can provide these women who are experiencing recurrent chest wall cancer with a better treatment for this devastating disease. We look forward to the outcomes of this trial in the hope of gaining increased local tumor control and improved quality of life for our patients."

To be eligible for participation in the trial, patients must have a confirmed diagnosis of RCW disease, had prior radiation to their chest wall and received two chemotherapy regimens.


'/>"/>

Contact: Nancy Jean
njean@lifespan.org
Lifespan
Source:Eurekalert

Related medicine news :

1. Maryjane A. Wurth Named New President of Illinois Hospital Association
2. l.a. Hospitals Struggle for Emergency Room Care, Pay Physicians High Fees for On-Call Coverage
3. reThinking eHealth Webinar Announced: Hospital Marketing in the eHealth Era
4. Senators Baucus and Grassley Statement Regarding Physician Hospitals Despicable
5. QHR Client Hospitals Lauded for Consistently High Quality Standards, Exceeding Patient Expectations
6. Baylor Dallas Recognized In U.S. News Media Groups 2009 - 2010 Americas Best Hospitals
7. Auroras Milwaukee Hospitals Recognized in US News and World Report
8. The Mount Sinai Medical Center Named to "Honor Roll" in U.S. News's 2009-10 Edition of America's Best Hospitals
9. Northwestern Memorial Among Americas Best Hospitals in 11 Clinical Specialties According to U.S. News 2009 Rankings
10. Ochsner Medical Center, Only Louisiana Hospital Listed in Americas Best by U.S. News
11. National Jewish Health Named Top Respiratory Hospital for 12th Consecutive Year
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:3/28/2017)... ... 28, 2017 , ... Silicon Valley Hair Institute, the San Francisco Bay Area ... about women’s hair loss. Although hair transplant procedures can be seen as more of ... genetics can be two reasons a woman may see her hair thinning. , “We ...
(Date:3/28/2017)... MO (PRWEB) , ... March 28, 2017 , ... ... of job satisfaction in their profession as their value increases in the healthcare ... that provides resources such as job boards, career fairs, and candidate leads to ...
(Date:3/27/2017)... ... March 27, 2017 , ... New patients who have sleep apnea ... treatment, with or without a referral. Sleep apnea is often left untreated because patients ... morning headaches and chronic snoring. , Dr. Braasch seeks to raise awareness of ...
(Date:3/27/2017)... Ohio (PRWEB) , ... March 27, 2017 , ... New ... OH to replace their missing teeth can now have them placed by Dr. Manju ... the latest i-CAT® Cone Beam technology to increase the accuracy of each dental implant ...
(Date:3/27/2017)... ... 2017 , ... This is the second major release since ... 2014. It is the culmination of collaborative efforts by members of the OSEHRA ... Member Zato Health co-funded the ONC certification and provided key technical support throughout ...
Breaking Medicine News(10 mins):
(Date:3/28/2017)... Mass. , March 28, 2017 ... company developing innovative therapeutics that address significant unmet ... a patent from the Japan Patent Office (JPO) ... connective tissue growth factor (CTGF) for the treatment ... limited to skin fibrosis and proliferative retinopathy (Japanese ...
(Date:3/28/2017)... Taiwan , March 28, 2017  Medeon ... medical device company, is pleased to announce that ... A investment of Panther Orthopedics, Inc., a ... innovative dynamic fixation solutions for orthopedic extremity applications.  ... continues to expand rapidly, primarily due to procedure ...
(Date:3/27/2017)... , March 27, 2017 ... to better understand Bayer and its partnering interests and activities ... 2010 report provides an in-depth insight into the partnering activity ... On demand company reports are prepared upon purchase to ... company data. The report will be delivered in ...
Breaking Medicine Technology: